keyword
MENU ▼
Read by QxMD icon Read
search

Taxan

keyword
https://www.readbyqxmd.com/read/28718092/no-significant-impact-of-prior-treatment-profile-with-docetaxel-on-the-efficacy-of-cabazitaxel-in-japanese-patients-with-metastatic-castration-resistant-prostate-cancer
#1
Hideaki Miyake, Takayuki Sugiyama, Ryota Aki, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Atsushi Otsuka
The objective of this study was to retrospectively analyze the oncological outcomes of Japanese patients with metastatic castration-resistant prostate cancer (mCRPC) who received cabazitaxel. This study included a total of 63 consecutive Japanese mCRPC patients treated with cabazitaxel following the failure of docetaxel, and assessed the prognostic significance of cabazitaxel therapy in these patients focusing on the association of efficacies between two taxane agents. After treatment with cabazitaxel (median 5 cycles), prostate-specific antigen (PSA) decline was observed in 39 patients (61...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28717760/pilot-survey-of-breast-cancer-management-in-sub-saharan-africa
#2
Verna D N K Vanderpuye, Olufunmilayo I Olopade, Dezheng Huo
PURPOSE: To understand the current state of breast cancer management in sub-Saharan Africa. METHODS: We conducted an anonymous online survey of breast cancer management among African Organization for Research and Treatment in Cancer (AORTIC) members by using a 42-question structured questionnaire in both English and French in 2013. RESULTS: Twenty members from 19 facilities in 14 countries responded to the survey. Twelve members (60%) belonged to a multidisciplinary breast cancer team...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717401/novel-therapeutic-strategies-in-the-treatment-of-triple-negative-breast-cancer
#3
REVIEW
Karima Oualla, Heba M El-Zawahry, Banu Arun, James M Reuben, Wendy A Woodward, Heba Gamal El-Din, Bora Lim, Nawfel Mellas, Naoto T Ueno, Tamer M Fouad
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels...
July 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28715532/germline-mutation-status-pathological-complete-response-and-disease-free-survival-in-triple-negative-breast-cancer-secondary-analysis-of-the-geparsixto-randomized-clinical-trial
#4
Eric Hahnen, Bianca Lederer, Jan Hauke, Sibylle Loibl, Sandra Kröber, Andreas Schneeweiss, Carsten Denkert, Peter A Fasching, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Sherko Kümmel, Christian Schem, Guido Neidhardt, Jens Huober, Kerstin Rhiem, Serban Costa, Janine Altmüller, Claus Hanusch, Holger Thiele, Volkmar Müller, Peter Nürnberg, Thomas Karn, Valentina Nekljudova, Michael Untch, Gunter von Minckwitz, Rita K Schmutzler
Importance: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germline mutation status affects treatment outcome remains elusive. Objective: To determine whether BRCA1 and BRCA2 germline mutation status affects therapy response in patients with TNBC...
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28710865/neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-a-multicentric-retrospective-observational-study-in-real-life-setting
#5
Teresa Gamucci, Laura Pizzuti, Isabella Sperduti, Lucia Mentuccia, Angela Vaccaro, Luca Moscetti, Paolo Marchetti, Luisa Carbognin, Andrea Michelotti, Laura Iezzi, Alessandra Cassano, Antonino Grassadonia, Antonio Astone, Andrea Botticelli, Emanuela Magnolfi, Luigi Di Lauro, Domenico Sergi, Paola Fuso, Nicola Tinari, Maddalena Barba, Marcello Maugeri-Saccà, Elisabetta Landucci, Francesca Conti, Giuseppe Sanguineti, Michele De Tursi, Gianni Iafrate, Antonio Giordano, Gennaro Ciliberto, Clara Natoli, Patrizia Vici
We aimed to assess the efficacy of neoadjuvant chemotherapy (NACT) in a cohort of 213 triple-negative breast cancer (TNBC) patients treated in real-world practice at 8 Italian cancer centres. We computed descriptive statistics for all the variable of interest. Factors testing significant in univariate analysis were included in multivariate models. Survival data were compared by Kaplan-Meier curves and log-rank test. The median follow-up was 45 months. We observed 60 (28.2%) pathological complete response (pCR)...
July 15, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/28706257/efficacy-and-safety-of-taxane-based-systemic-chemotherapy-of-advanced-gastric-cancer-a-systematic-review-and-meta-analysis
#6
Jinxin Shi, Peng Gao, Yongxi Song, Xiaowan Chen, Yuan Li, Changwang Zhang, Hongchi Wang, Zhenning Wang
Taxanes are chemotherapeutic agents commonly used to treat several cancers. However, the effects of taxanes on advanced gastric cancer (AGC) are still not clear, especially when used as a first-line treatment. This systematic review and meta-analysis aims to investigate the efficacy and safety of taxanes as a first-line treatment of AGC. The quality of our included studies was assessed using the Cochrane risk of bias tool for RCTs and NOS scale for nRCTs, and the data of the included studies was of satisfactory quality to analyze...
July 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28705541/risk-factors-affecting-breast-cancer-related-lymphedema-serial-body-weight-change-during-neoadjuvant-anthracycline-plus-cyclophosphamide-followed-by-taxane
#7
Sungmin Park, Jeong Eon Lee, Jonghan Yu, Hyun-June Paik, Jai Min Ryu, Isaac Kim, Soo Youn Bae, Se Kyung Lee, Seok Won Kim, Seok Jin Nam, Eun-Kyu Kim, Eunyoung Kang, Eun Joo Yang
INTRODUCTION: The aim of our study was to analyze the risk of lymphedema (LE) according to the clinicopathologic factors and to investigate the serial change in body weight during neoadjuvant anthracycline plus cyclophosphamide followed by taxane and its correlation with the incidence of LE. PATIENTS AND METHODS: We performed a retrospective 2-center study of 406 patients who had undergone neoadjuvant chemotherapy (NAC) followed by surgery from 2007 to 2014. The regimen included 4 cycles of anthracycline plus cyclophosphamide, followed by 4 cycles of taxane...
June 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28702770/oncologic-outcomes-after-treatment-for-mri-occult-breast-cancer-pt0n
#8
Damian P McCartan, Emily C Zabor, Monica Morrow, Kimberly J Van Zee, Mahmoud B El-Tamer
BACKGROUND: Studies assessing outcomes in occult breast cancer have often included women treated before the routine use of magnetic resonance imaging (MRI). This study examined outcomes for patients presenting with axillary adenopathy and no primary breast tumor detectable by MRI or other imaging methods. METHODS: All patients with axillary nodal metastases consistent with breast carcinoma and no breast primary tumor detectable by physical exam, mammography, or MRI treated between 1 January 1996 and 30 June 2011 were identified from an institutional database...
July 12, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28702748/-splice-variant-ar-v7-is-it-time-for-its-routine-use-as-a-predictive-marker-in-prostate-cancer
#9
REVIEW
I Tsaur, C Becker, P Thelen, F C Roos
Androgen receptor splice variants (AR-Vs), if overexpressed, lack the ligand-binding domain conveying metastasized castration-resistant prostate cancer with a therapeutic resistance to androgen receptor signaling inhibitors. Particularly AR-V7 has recently been proposed as a potential predictive biomarker to identify patients who would probably benefit most from taxane-based cytotoxic treatment. Several assays to substantiate or quantify AR-V7 expression have recently been proposed. However, their broad clinical value is still debatable...
July 12, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28701571/neoadjuvant-therapy-with-weekly-nanoparticle-albumin-bound-paclitaxel-for-luminal-early-breast-cancer-patients-results-from-the-nabrax-study-geicam-2011-02-a-multicenter-non-randomized-phase-ii-trial-with-a-companion-biomarker-analysis
#10
Miguel Martín, José I Chacón, Antonio Antón, Arrate Plazaola, Elena García-Martínez, Miguel A Seguí, Pedro Sánchez-Rovira, José Palacios, Lourdes Calvo, Carmen Esteban, Enrique Espinosa, Agusti Barnadas, Norberto Batista, Angel Guerrero, Montserrat Muñoz, Estefania Romio, César Rodríguez-Martín, Rosalía Caballero, María I Casas, Federico Rojo, Eva Carrasco, Silvia Antolín
BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel) is an alternative to standard taxanes for breast cancer (BC) treatment. We evaluated nab-Paclitaxel efficacy as neoadjuvant treatment for early estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) disease. MATERIALS AND METHODS: Women with ER+, HER2-, stage II-III BC were treated preoperatively with four cycles of weekly nab-Paclitaxel (150 mg/m(2)), 3 weeks on and 1 week off...
July 12, 2017: Oncologist
https://www.readbyqxmd.com/read/28698198/abcb1-mediates-cabazitaxel-docetaxel-cross-resistance-in-advanced-prostate-cancer
#11
Alan P Lombard, Chengfei Liu, Cameron M Armstrong, Vito Cucchiara, Xinwei Gu, Wei Lou, Christopher P Evans, Allen C Gao
in research have added several new therapies for castration-resistant prostate cancer (CRPC), greatly augmenting our ability to treat patients. However, CRPC remains an incurable disease due to the development of therapeutic resistance and the existence of cross-resistance between available therapies. Understanding the interplay between different treatments will lead to improved sequencing and the creation of combinations which overcome resistance and prolong survival. Whether there exists cross-resistance between docetaxel and the next-generation taxane cabazitaxel is poorly understood...
July 11, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28693250/bcl-2-bcl-xl-inhibitor-abt-737-sensitizes-pancreatic-ductal-adenocarcinoma-to-paclitaxel-induced-cell-death
#12
Shuya Kasai, Takuya Sasaki, Ayano Watanabe, Masao Nishiya, Shinji Yasuhira, Masahiko Shibazaki, Chihaya Maesawa
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignant disease that is resistant to various chemotherapeutic agents and commonly relapses. Efficient elimination of metastasized PDA is critical for a positive post-surgical treatment outcome. The present study analyzed the effect of the B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma extra-large (Bcl-xL) inhibitor, ABT-737, on paclitaxel-induced PDA cell death. A total of 8 PDA cell lines were subjected to immunoblotting to compare the expression of Bcl-2/Bcl-xL and other factors associated with taxane resistance, including myeloid cell leukemia 1 and βIII-tubulin (TUBB3)...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28691093/wnt-antagonists-exhibit-unique-combinatorial-antitumor-activity-with-taxanes-by-potentiating-mitotic-cell-death
#13
Marcus M Fischer, Belinda Cancilla, V Pete Yeung, Fiore Cattaruzza, Cecile Chartier, Christopher L Murriel, Jennifer Cain, Raymond Tam, Chieh-Yang Cheng, James W Evans, Gilbert O'Young, Xiaomei Song, John Lewicki, Ann M Kapoun, Austin Gurney, Wan-Ching Yen, Timothy Hoey
The WNT pathway mediates intercellular signaling that regulates cell fate in both normal development and cancer. It is widely appreciated that the WNT pathway is frequently dysregulated in human cancers through a variety of genetic and epigenetic mechanisms. Targets in the WNT pathway are being extensively pursued for the development of new anticancer therapies, and we have advanced two WNT antagonists for clinical development: vantictumab (anti-FZD) and ipafricept (FZD8-Fc). We examined the antitumor efficacy of these WNT antagonists in combination with various chemotherapies in a large set of patient-derived xenograft models...
June 2017: Science Advances
https://www.readbyqxmd.com/read/28690105/de-escalating-and-escalating-systemic-therapy-in-triple-negative-breast-cancer
#14
Lisa A Carey
Triple negative breast cancer has the highest relapse risk of all the clinical subsets, although the escalation of chemotherapy has benefited this subset substantially over recent years. Systemic options are limited to chemotherapy, which makes meaningful de-escalation or escalation of therapy more challenging but possible. Observational cohorts suggest a less than 10% risk of relapse and minimal if any benefit of chemotherapy in very small (<1 cm), node-negative triple negative disease. In higher risk, particularly node-positive disease, anthracycline/taxane-based regimens remain standard...
July 7, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28688674/a-network-meta-analysis-of-the-sequencing-and-types-of-systemic-therapies-with-definitive-radiotherapy-in-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-lascchn-%C3%A2
#15
Katarzyna J Jerzak, Keemo Delos Santos, Ronak Saluja, Kelly Lien, Justin Lee, Kelvin K W Chan
OBJECTIVES: The current standard therapy for locally advanced squamous cell carcinoma of the head and neck (LASCCHN) is platinum-based chemotherapy plus concurrent radiotherapy (CRT), but several systemic therapies have been evaluated. We performed a Bayesian network meta-analysis (NMA) with random effects to enable direct and indirect comparisons of all existing treatment modalities for LASCCHN simultaneously. MATERIAL AND METHODS: A systematic review was conducted using MEDLINE, EMBASE, ASCO abstracts, ASTRO abstracts and the Cochrane Central of Registered Trials using Cochrane methodology to identify randomized controlled trials (RCTs) up to June 2016...
August 2017: Oral Oncology
https://www.readbyqxmd.com/read/28685075/combination-of-irinotecan-and-platinum-for-platinum-resistant-or-refractory-recurrent-ovarian-cancers-a-preliminary-case-series
#16
Takashi Shibutani, Masashi Takano, Morikazu Miyamoto, Tomoyuki Yoshikawa, Tadashi Aoyama, Hiroaki Soyama, Junko Hirata, Ayako Suzuki, Hidenori Sasa, Kenichi Furuya
Non-platinum single agents are usually used for patients with platinum-resistant recurrent ovarian cancers (ROC). However, the efficacy of these drugs is limited. The aim of the present study was to evaluate the efficacy and adverse events (AE) of combination therapy with irinotecan and platinum (CPT-Pt) for ROC. A total of 28 platinum-resistant or refractory patients with ROC treated with CPT-Pt at the National Defense Medical College Hospital institution between 2002 and 2012 were identified. All patients received taxane and carboplatin (TC) as a first-line treatment and relapsed within 6 months after completion of TC, or progressed during TC therapy...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28679644/a-phase-ii-multi-center-study-of-bevacizumab-in-combination-with-ixabepilone-in-subjects-with-advanced-renal-cell-carcinoma
#17
Mauricio Burotto, Maureen Edgerly, Margarita Velarde, Sanjeeve Balasubramaniam, Harry Drabkin, Juan G Gormaz, Ciara O'Sullivan, Ravi Madan, Tito Fojo
LESSONS LEARNED: Accrual to renal cell carcinoma trials remains a challenge despite the lack of prolonged response to the available treatments.The observation of three responses among the 30 patients with median progression-free survival and overall survival of 8.3 and 15 months, respectively, indicates the combination has some activity, but it is not sufficient for further development. BACKGROUND: Treatment of metastatic renal cell carcinoma (mRCC) remains suboptimal...
July 5, 2017: Oncologist
https://www.readbyqxmd.com/read/28678741/role-of-nab-paclitaxel-in-metastatic-breast-cancer-a-meta-analysis-of-randomized-clinical-trials
#18
Yun Liu, Guoxin Ye, Dali Yan, Lei Zhang, Fan Fan, Jifeng Feng
Whether nab-paclitaxel and conventional taxanes are equally effective for metastatic breast cancer (MBC) remains unclear. We conducted meta-analysis of trials that compared nab-paclitaxel-based chemotherapy with solvent-based paclitaxel (sb-paclitaxel) and docetaxel-based chemotherapy. A literature search was performed to identify articles that compared nab-paclitaxel-based chemotherapy with sb-paclitaxel or docetaxel-based chemotherapy for MBC. Four randomized controlled trials (1,506 patients) were identified from 1,268 reports...
June 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28677012/persistent-impairments-3%C3%A2-years-after-neo-adjuvant-chemotherapy-for-breast-cancer-results-from-the-matox-project
#19
Hans-Jürgen Hurtz, Hans Tesch, Thomas Göhler, Ulrich Hutzschenreuter, Johanna Harde, Lisa Kruggel, Martina Jänicke, Norbert Marschner
PURPOSE: Although treatment for early breast cancer improved prognosis greatly, it can have significant long-term consequences, which must be considered during treatment decision. METHODS: 453 patients with neoadjuvant or adjuvant treatment intention were recruited into the MaTox project within the prospective, multicentre, population-based German TMK cohort study (Tumour Registry Breast Cancer) between 2008 and 2009. Patient-reported outcomes (PROs) on 26 treatment-related symptoms were assessed via a specifically designed questionnaire at 4 weeks, 6 months, 18 months and 3 years after start of systemic treatment...
July 5, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28676659/mutations-in-brca2-and-taxane-resistance-in-prostate-cancer
#20
Cathleen Nientiedt, Martina Heller, Volker Endris, Anna-Lena Volckmar, Stefanie Zschäbitz, María A Tapia-Laliena, Anette Duensing, Dirk Jäger, Peter Schirmacher, Holger Sültmann, Albrecht Stenzinger, Markus Hohenfellner, Carsten Grüllich, Stefan Duensing
Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 mutations of the primary tumor. In a subgroup of patients, BRCA1/2 protein expression was tested as a potential surrogate marker for BRCA1/2 inactivation...
July 4, 2017: Scientific Reports
keyword
keyword
64691
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"